文献速递临床试验与 GCP流行病学与生物统计

比较埃塞俄比亚间日疟治疗中青蒿琥酯-本芴醇与氯喹联合或不联合伯氨喹的随机对照试验

Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.
PubMed 文献 · PLoS Med · 2017-05-16

在埃塞俄比亚开展随机对照试验,398例葡萄糖-6-磷酸脱氢酶正常且间日疟单感染患者随机接受氯喹或青蒿琥酯-本芴醇单用或联合14天半监督伯氨喹(总量3.5 mg/kg),随访1年。伯氨喹联合氯喹或青蒿琥酯-本芴醇耐受良好,使1年复发风险降低5倍。

要点

  • 第42天复发风险:氯喹18.7% vs 氯喹+伯氨喹1.2%;青蒿琥酯-本芴醇29.9% vs 青蒿琥酯-本芴醇+伯氨喹5.9%。
  • 未用伯氨喹者第42天复发风险青蒿琥酯-本芴醇组高于氯喹组(HR=1.8,95%CI 1.0-3.2;P=0.059),未达统计学显著。
  • 伯氨喹联合氯喹或青蒿琥酯-本芴醇使间日疟1年发病率降低约5倍,不良反应无组间差异。

核心结论

  • 尽管存在氯喹耐药间日疟证据,本研究中青蒿琥酯-本芴醇单用复发风险高于氯喹,除非联合监督伯氨喹疗程。
  • 伯氨喹联合氯喹或青蒿琥酯-本芴醇耐受良好,使间日疟1年复发风险降低5倍。

研究设计与样本

  • 在埃塞俄比亚开展的随机对照试验,纳入葡萄糖-6-磷酸脱氢酶正常且症状性间日疟单感染患者。
  • 398例患者随机分配至氯喹组(n=104)、青蒿琥酯-本芴醇组(n=100)、氯喹+伯氨喹组(n=102)、青蒿琥酯-本芴醇+伯氨喹组(n=92),随访1年。
  • 伯氨喹方案为14天半监督给药,总量3.5 mg/kg;复发 episodes 按入组时分配方案再治疗。

主要发现

  • 第28天复发风险:氯喹组4.0%(95%CI 1.5%-10.4%),氯喹+伯氨喹组0%(95%CI 0%-4.0%),青蒿琥酯-本芴醇组12.0%(95%CI 6.8%-20.6%),青蒿琥酯-本芴醇+伯氨喹组2.3%(95%CI 0.6%-9.0%)。
  • 第42天复发风险:氯喹组18.7%(95%CI 12.2%-28.0%),氯喹+伯氨喹组1.2%(95%CI 0.2%-8.0%),青蒿琥酯-本芴醇组29.9%(95%CI 21.6%-40.5%),青蒿琥酯-本芴醇+伯氨喹组5.9%(95%CI 2.4%-13.5%),总体P<0.001。
  • 未用伯氨喹者第42天复发风险青蒿琥酯-本芴醇组高于氯喹组(HR=1.8,95%CI 1.0-3.2;P=0.059)。
  • 随访结束时间日疟发病率:氯喹组2.2次/人年 vs 氯喹+伯氨喹组0.4次/人年(率比5.1,95%CI 2.9-9.1;P<0.001);青蒿琥酯-本芴醇组2.3次/人年 vs 青蒿琥酯-本芴醇+伯氨喹组0.5次/人年(率比6.4,95%CI 3.6-11.3;P<0.001)。
  • 治疗组间不良反应发生无差异。

关键数值与推荐

  • 第28天复发风险:氯喹组4.0%(95%CI 1.5%-10.4%),氯喹+伯氨喹组0%(95%CI 0%-4.0%),青蒿琥酯-本芴醇组12.0%(95%CI 6.8%-20.6%),青蒿琥酯-本芴醇+伯氨喹组2.3%(95%CI 0.6%-9.0%)。
  • 第42天复发风险:氯喹组18.7%(95%CI 12.2%-28.0%),氯喹+伯氨喹组1.2%(95%CI 0.2%-8.0%),青蒿琥酯-本芴醇组29.9%(95%CI 21.6%-40.5%),青蒿琥酯-本芴醇+伯氨喹组5.9%(95%CI 2.4%-13.5%),总体P<0.001。
  • 未用伯氨喹者第42天复发风险青蒿琥酯-本芴醇组 vs 氯喹组 HR=1.8(95%CI 1.0-3.2;P=0.059)。
  • 间日疟发病率:氯喹组2.2次/人年 vs 氯喹+伯氨喹组0.4次/人年(率比5.1,95%CI 2.9-9.1;P<0.001);青蒿琥酯-本芴醇组2.3次/人年 vs 青蒿琥酯-本芴醇+伯氨喹组0.5次/人年(率比6.4,95%CI 3.6-11.3;P<0.001)。

临床怎么用

  • 伯氨喹联合氯喹或青蒿琥酯-本芴醇耐受良好,使间日疟1年复发风险降低5倍。
  • 未联合伯氨喹时,青蒿琥酯-本芴醇单用第42天复发风险高于氯喹单用(HR=1.8,95%CI 1.0-3.2;P=0.059),未达统计学显著。

局限性

  • 试验提前终止。
  • 第42天后未测量血红蛋白,导致无法估计贫血累积风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent efforts in malaria control have resulted in great gains in reducing the burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form dormant liver stages confounds control and elimination efforts. To compare the efficacy and safety of primaquine regimens for radical cure, we undertook a randomized controlled trial in Ethiopia. METHODS AND FINDINGS: Patients with normal glucose-6-phosphate dehydrogenase status with symptomatic P. vivax mono-infection were enrolled and randomly assigned to receive either chloroquine (CQ) or artemether-lumefantrine (AL), alone or in combination with 14 d of semi-supervised primaquine (PQ) (3.5 mg/kg total). A total of 398 patients (n = 104 in the CQ arm, n = 100 in the AL arm, n = 102 in the CQ+PQ arm, and n = 92 in the AL+PQ arm) were followed for 1 y, and recurrent episodes were treated with the same treatment allocated at enrolment. The primary endpoints were the risk of P. vivax recurrence at day 28 and at day 42. The risk of recurrent P. vivax infection at day 28 was 4.0% (95% CI 1.5%-10.4%) after CQ treatment and 0% (95% CI 0%-4.0%) after CQ+PQ. The corresponding risks were 12.0% (95% CI 6.8%-20.6%) following AL alone and 2.3% (95% CI 0.6%-9.0%) following AL+PQ. On day 42, the risk was 18.7% (95% CI 12.2%-28.0%) after CQ, 1.2% (95% CI 0.2%-8.0%) after CQ+PQ, 29.9% (95% CI 21.6%-40.5%) after AL, and 5.9% (95% CI 2.4%-13.5%) after AL+PQ (overall p < 0.001). In those not prescribed PQ, the risk of recurrence by day 42 appeared greater following AL treatment than CQ treatment (HR = 1.8 [95% CI 1.0-3.2]; p = 0.059). At the end of follow-up, the incidence rate of P. vivax was 2.2 episodes/person-year for patients treated with CQ compared to 0.4 for patients treated with CQ+PQ (rate ratio: 5.1 [95% CI 2.9-9.1]; p < 0.001) and 2.3 episodes/person-year for AL compared to 0.5 for AL+PQ (rate ratio: 6.4 [95% CI 3.6-11.3]; p < 0.001). There was no difference in the occurrence of adverse events between treatment arms. The main limitations of the study were the early termination of the trial and the omission of haemoglobin measurement after day 42, resulting in an inability to estimate the cumulative risk of anaemia. CONCLUSIONS: Despite evidence of CQ-resistant P. vivax, the risk of recurrence in this study was greater following treatment with AL unless it was combined with a supervised course of PQ. PQ combined with either CQ or AL was well tolerated and reduced recurrence of vivax malaria by 5-fold at 1 y. TRIAL REGISTRATION: ClinicalTrials.gov NCT01680406.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Abreha T, Hwang J, Thriemer K, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Med. 2017. PMID: 28510573. doi:10.1371/journal.pmed.1002299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。